Novartis had filed multiple qua timet patent infringement lawsuits against a number of generic companies including Biocon, Glenmark, Wockhardt Ajanta Pharma etc. and has managed to secure several interim injunctions against these generic companies. In 37 of these infringement lawsuits, Novartis either secured an interim injunction or a settlement from the defendant making this series of litigation one of the most successful enforcement campaigns in the 12 years since India started granting pharmaceutical patents from 2005.